石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

已收盘 09-02 16:08:07

9.170

-0.060

-0.65%

最高9.375	最低9.100	成交量6,580万
今开9.330	昨收9.230	日振幅2.98%
总市值1,057亿	流通市值1,057亿	总股本115.22亿
成交额6.05亿	换手率0.57%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":9.17,"timestamp":1788336487003,"preClose":9.23,"halted":0,"volume":65804858,"delay":0,"changeRate":-0.006500541711809371,"floatShares":11522000000,"shares":11522000000,"eps":0.3963636004297803,"marketStatus":"已收盘","change":-0.06,"latestTime":"09-02 16:08:07","open":9.33,"high":9.375,"low":9.1,"amount":605411086,"amplitude":0.029794,"askPrice":9.17,"askSize":40000,"bidPrice":9.165,"bidSize":68000,"shortable":3,"etf":0,"ttmEps":0.7587983366873975,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":5,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":9.23,"dividendRate":0.031636,"openAndCloseTimeList":[[1788312600000,1788321600000],[1788325200000,1788336000000]],"volumeRatio":0.564789,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":true,"expireDate":1798560000000,"strike":"12.00","timestamp":1788321372650,"price":0.3,"volume":318,"amount":190800,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.4944,"impliedVolPercentile":0.3347},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2664529860","title":"港股早盘偏软 恒指低开0.19% 洛阳钼业（03993）跌3.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664529860","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664529860?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:26","pubTimestamp":1788312365,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘偏软，恒指低开0.19%，国企指数低开0.18%，恒生科技指数低开0.41%。先声药业高开4.82%，公司宣布，于2026年9月1日，集团与F.Hoffmann-LaRocheLtd签署独家授权许可协议）。根据该协议条款，罗氏将获得SIM0660的全球范围内独家开发、生产与商业化权益。港股表现受压，加息预期再度升温，不利大市气氛，指数低开后持续向下，低见25,200点水平，其后跌幅稍为收窄，整体成交保持清淡。蓝筹股普遍下跌，科网股及内房股持续弱势，资金则流入内银股避险。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990339","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00992","KURE","LU0588545904.SGD","LU0320764755.SGD","601939","LU2097828557.USD","HK0000288784.HKD","LU0737861699.HKD","601899","LU1993786604.SGD","BK1540","LU0315179316.USD","HK0000107257.USD","HK0000306701.USD","LU0540923850.HKD","LU1481107354.HKD","LU0431992006.USD","BK1190","LU0499858438.USD","LU1568876251.USD","LU0890818403.SGD","LU1235295612.USD","BK1607","BK1504","LU0264606111.USD","IE00B3M56506.USD","LU0287142896.SGD","LU0516422366.SGD","LU1522347837.USD","LU0531971595.HKD","01093","LU1251922891.USD","HK0000306685.HKD","LU1044876610.USD","LU0886674414.USD","LU0828237940.HKD","LU0417516738.SGD","LU0326950275.SGD","LU1282648689.USD","LU0918141705.HKD","LU0737861772.HKD","LU0348814723.USD","LU1568876335.HKD","SG9999002463.SGD","03143","LU0128522157.USD","IE00B543WZ88.USD","LU1988902786.USD","LU0348827113.USD","LU0588545490.SGD","LU0828237510.HKD","LU0880133367.SGD","HK0000286598.CNH","LU0072913022.USD","02800","LU1504937902.USD","LU0516423091.SGD","LU0329678170.USD","LU0918141887.USD","LU0823040885.USD","LU1044874839.SGD","03419","LU0228367735.SGD","LU1226287529.USD","LU1323998911.USD","LU1282651048.USD","LU0463099449.HKD","LU1226288170.HKD","LU1720050803.USD","LU1105468828.SGD","BK1231","LU0211977185.USD","LU1046422090.SGD","LU0348766576.USD","IE00BQJZWZ67.USD","LU2187417386.USD","LU0244354667.USD","LU0831093199.SGD","LU0501845795.SGD","HK0000320223.HKD","LU0165289439.USD","LU0862451837.USD","LU0329678337.USD","BK1505","06181","IE00B0JY6N72.USD","LU0140636845.USD","09633","LU2097828631.EUR","LU0797268264.HKD","LU0823038988.USD","LU1769817179.HKD","BK1521","LU0396098781.USD","LU1642822792.SGD","LU0979878070.USD","LU1981816686.USD","LU0052756011.USD","LU0293314216.USD","LU1064131003.USD","LU1224709979.USD","SG9999013353.USD","LU2039709279.SGD","LU0029875118.USD","LU0708995583.HKD","BK1594","LU0823039010.USD","IE00B19Z5X02.USD","BK1528","LU2097828805.USD","LU0572940350.SGD","LU0084288322.USD","LU0052750758.USD","LU1048484197.HKD","02096","LU0128525689.USD","LU0865486749.SGD","03993","LU0231483743.USD","LU0516423174.USD","LU0819123356.HKD","BK1583","IE00BVYPNQ40.USD","BK1238","LU0516422440.USD","BK1582","03115","LU1211504680.USD","IE00BGHQDM52.EUR","LU2929501877.USD","LU0370786039.SGD","LU0611395673.USD","LU0164880469.USD","LU0972618739.USD","SG9999002562.SGD","BK1149","LU0456854461.SGD","LU0791590937.USD","IE00BVYPNP33.GBP","SG9999001051.SGD","BK1515","CICHY","LU0345775950.USD","BK1193","LU0345780521.USD","LU0633140560.USD","LU0828238088.HKD","600938","LU0348735423.USD","LU0348805143.USD","LU0310800965.SGD","LU0314109678.HKD","IE0003895053.USD","IE00BWDBJ730.SGD","01519","LU0572939691.SGD","LU0417516902.SGD","LU1961090484.USD","BK1191","LU0149721374.USD","LU0315178854.USD","LU0672654166.SGD","LU1719994722.HKD","LU0359201612.USD","80992","LU0164939612.USD","LU0348825331.USD","LU0509642566.USD","LU1226287792.SGD","BK1526","LU2097828474.EUR","LU1634259391.SGD","LU1242518931.SGD","07200","LU0082770016.USD","02833","LU2213484517.USD","LU0630378429.USD","LU1044875133.USD","LU0868486357.SGD","LU0269904917.USD","83115","HSTECH","LU0266512127.USD","LU0266512473.USD","LU1813983027.USD","LU1152091168.USD","MCHmain","07300","LU0683595622.HKD","BK1198","BK1544","00883","BK1227","HHImain","HK0000320264.USD","LU0181495838.USD","LU2351347302.SGD","LU1064130708.USD","LU2264538146.SGD","LU0173614495.USD","LU2399975544.HKD","LU1880383366.USD","LU0049853897.USD","BK1167","513600","LU1634259557.SGD","LU0327786744.USD","NNFSF","LU1831875114.USD","LU0543330483.HKD","LU1880383440.USD","SG9999014674.SGD","LU1366334578.USD","HK0001040168.HKD","LU1497734951.SGD","LU1951186391.HKD","IE0032431581.USD","ZIJMY","LU0067412154.USD","LU1807302812.USD","LU1770034418.SGD","LU0307460666.USD","SG9999004311.SGD","LU1808992512.USD","LU0048580855.USD","LU1769817096.USD","BK1560","LU0320764599.SGD","IE0034224299.USD","82800","LU0359201885.HKD","LU1794554557.SGD","LU0856984785.SGD","IE00BYV24P56.USD","00285","LU0634319403.HKD","HK0000165453.HKD","LU0043850808.USD","LU0082770016.SGD","BK1589","LU0164865239.USD","IE00BZ08YT58.USD","BK1580","IE0008369823.USD","LU1328277881.USD","LU0163747925.USD","LU2177674079.SGD","LU1152091754.HKD","LU0499858602.USD","HK0000288743.USD","09973","LU0469268626.HKD","BK1200","LU0047713382.USD","LU0821914370.USD","03037","LU0345780281.USD","BK1610","LU0359202008.SGD","LU1188198961.HKD","LU0572944931.SGD","LU0061477393.USD","LU0819121731.USD","LU1226288253.USD","SG9999009443.AUD","SG9999007991.SGD","LU2087589342.USD","LU0561508036.HKD","BK1151","LU1770036033.HKD","LU1064131342.USD","LNVGY","IE00BZ08YS42.EUR","LU0228659784.USD","LU1048596156.SGD","IE00BPRC5H50.USD","LU1224444064.USD","LU1282651121.HKD","LU0862451753.SGD","BK1592","LU0791591158.USD","LU1960683339.HKD","SG9999004220.SGD","LU0348816934.USD","LU0588545730.USD","IE00BMCWC346.EUR","LU1785774172.SGD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","07500","00939","LU0633140727.USD","LU1497733631.SGD","LU0328353924.USD","LU0348767384.USD","LU0106252389.USD","TCHI","LU0106959298.USD","LU0049112450.USD","LU0516422952.EUR","LU0588546209.SGD","80883","LU0620787316.HKD","LU2226246903.HKD","SGXZ90724238.SGD","LU0675040207.SGD","LU2242644610.SGD","LU0762540952.USD","LU0871576103.HKD","LU1226287875.USD","LU0039217434.USD","LU0345776255.USD","LU1242518857.USD","LU0096374516.USD","LU0441854154.USD","LU1267930227.SGD","LU1303224171.USD","02899","09115","LU2008162690.USD","BK1119","IE0008368742.USD","HK0001040143.USD","LU2148510915.USD","SG9999002828.SGD","IE00B031HY20.USD","LU0274383008.USD","HSI","LU3063872942.SGD","LU1497733557.USD","LU1366334651.USD","LU2097828714.EUR","LU1023057109.AUD","603993","LU1008478684.HKD","LU0259732245.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125248864","title":"石药集团SYS6010获国家药监局突破性治疗认定，针对复发/转移性头颈鳞状细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1125248864","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125248864?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:15","pubTimestamp":1788257709,"startTime":"0","endTime":"0","summary":"石药集团近日宣布，其核心在研产品SYS6010已获得中国国家药品监督管理局（NMPA）授予的突破性治疗药物认定。此番认定适用于复发或转移性头颈鳞状细胞癌（R/M HNSCC）的治疗领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072913022.USD","SG9999004220.SGD","LU0501845795.SGD","LU1226287529.USD","KURE","IE0008368742.USD","LU1993786604.SGD","LU2039709279.SGD","LU0315179316.USD","LU1807302812.USD","LU0140636845.USD","LU1152091168.USD","LU1226288170.HKD","BK1521","LU1328277881.USD","IE00BZ08YR35.GBP","LU1226288253.USD","BK1515","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU1008478684.HKD","LU1226287875.USD","LU1813983027.USD","IE00BZ08YT58.USD","LU0314109678.HKD","LU1951186391.HKD","LU0326950275.SGD","LU0067412154.USD","IE00B031HY20.USD","BK1191","IE0008369823.USD","LU1226287792.SGD","LU1960683339.HKD","LU1152091754.HKD","IE00B5MMRT66.SGD","HK0000165453.HKD","01093","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199784900","title":"石药集团发布2026年8月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1199784900","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199784900?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:12","pubTimestamp":1788257573,"startTime":"0","endTime":"0","summary":"2026年9月1日，石药集团有限公司公布截至2026年8月31日的股份变动月报表。报告显示，公司截至2026年8月底的普通股已发行股份总数为11,522,451,732股，与上月底相比未发生变动，库存股份数亦为0股，股本规模保持稳定。报告期内，公司未进行新增发行、购回或注销股份活动。公司确认截至报告期末，其已满足香港联交所《上市规则》规定的适用公众持股量要求，并予以继续遵守。上述公告由公司秘书罗泰安签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664858828","title":"石药集团(01093.HK)：SYS6010于中国再获国家药监局纳入突破性治疗品种名单用于治疗复发或转移性头颈鳞癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2664858828","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664858828?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:09","pubTimestamp":1788257376,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","LU1960683339.HKD","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU0880133367.SGD","LU1328277881.USD","LU0501845795.SGD","LU1008478684.HKD","KURE","BK1521","IE00BZ08YR35.GBP","IE0008368742.USD","LU1813983027.USD","01093","IE00B543WZ88.USD","LU1951186391.HKD","SG9999004220.SGD","BK1515","LU0072913022.USD","LU1226287529.USD","LU1226287792.SGD","LU2039709279.SGD","LU1226288170.HKD","IE00BZ08YS42.EUR","LU0315179316.USD","LU1993786604.SGD","LU0314109678.HKD","IE00BZ08YT58.USD","LU1226287875.USD","HK0000165453.HKD","LU0067412154.USD","IE0008369823.USD","LU1152091754.HKD","LU0140636845.USD","LU0326950275.SGD","LU1152091168.USD","LU1226288253.USD","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664830025","title":"石药集团：SYS6010再获国家药监局纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2664830025","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664830025?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:09","pubTimestamp":1788257367,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0008369823.USD","IE0008368742.USD","BK1521","LU0880133367.SGD","LU1008478684.HKD","LU1226287875.USD","LU1807302812.USD","LU1951186391.HKD","LU1960683339.HKD","LU1226288170.HKD","LU0314109678.HKD","BK1191","LU0067412154.USD","LU1226287792.SGD","LU0140636845.USD","LU1226288253.USD","LU0315179316.USD","LU1328277881.USD","LU1226287529.USD","01093","LU1152091168.USD","LU1993786604.SGD","LU1152091754.HKD","HK0000165453.HKD","LU2039709279.SGD","LU0501845795.SGD","LU0326950275.SGD","BK1515","IE00B543WZ88.USD","LU1813983027.USD","SG9999004220.SGD","KURE","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00B031HY20.USD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191469308","title":"石药集团（01093）启动SYH2092注射液中国首个I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1191469308","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191469308?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:06","pubTimestamp":1788177993,"startTime":"0","endTime":"0","summary":"石药集团有限公司8月31日公告，集团自主研发的胰淀素受体激动剂SYH2092注射液用于成人超重或肥胖患者体重管理的I期临床试验已在中国首个研究中心正式启动。SYH2092通过优化激动活性及脂肪酸修饰，旨在在可控耐受性基础上提升疗效并延长体内半衰期。该试验将评估SYH2092在健康受试者中的单次给药安全性、耐受性、药代动力学及药效学。石药集团表示，SYH2092有望为肥胖人群的体重管理以及2型糖尿病成人患者的血糖控制提供新的治疗选择。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663087520","title":"石药集团：SYH2092注射液I期临床试验在中国首个研究中心启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2663087520","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663087520?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:03","pubTimestamp":1788177780,"startTime":"0","endTime":"0","summary":"南财智讯8月31日电，石药集团（01093.HK）发布自愿公告，公司开发的SYH2092注射液用于成人超重或肥胖患者体重管理的I期临床试验已在中国首个研究中心正式启动。该产品为胰淀素（Amylin）受体激动剂，通过优化激动活性及脂肪酸修饰，旨在提升疗效、改善耐受性并延长体内半衰期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860264998.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860264998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","LU1807302812.USD","PSYK","IE00BZ08YT58.USD","LU1993786604.SGD","LU1226287529.USD","IE00BZ08YR35.GBP","LU0880133367.SGD","IE00B031HY20.USD","BK1191","01093","LU1226288170.HKD","LU1152091754.HKD","KURE","IE0008368742.USD","LU1813983027.USD","BK1521","LU0067412154.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","LU0315179316.USD","IE00B543WZ88.USD","LU1008478684.HKD","BK1515","IBBJ","IE0008369823.USD","LU1328277881.USD","BMED","LU1226288253.USD","LU0140636845.USD","LU0326950275.SGD","LU0501845795.SGD","LU1152091168.USD","LU1226287792.SGD","MDTX","SG9999004220.SGD","LU0314109678.HKD","LU1960683339.HKD","LU2039709279.SGD","LU1226287875.USD","LU0072913022.USD","IE00B5MMRT66.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136656281","title":"石药集团启动SYH2092注射液中国体重管理I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1136656281","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136656281?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:53","pubTimestamp":1788177190,"startTime":"0","endTime":"0","summary":"石药集团近日宣布，已在中国正式启动SYH2092注射液的I期临床试验，该试验旨在评估其在体重管理领域的应用潜力。\n据悉，这项临床研究将重点考察SYH2092注射液的安全性、耐受性及药代动力学特征，为后续的临床开发奠定基础。\n作为一家专注于创新药物研发的制药企业，石药集团正在积极推进其代谢疾病领域的管线布局。此次SYH2092注射液的临床试验启动，也标志着该公司在体重管理这一热门赛道上的又一重要进展。\n业内分析人士指出，随着全球肥胖人口持续攀升，体重管理药物市场正迎来前所未有的发展机遇。石药集团此举无疑将进一步丰富其在该领域的产品储备，有望在未来竞争中占据有利位置。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","KURE","LU0314109678.HKD","LU0501845795.SGD","LU1226287529.USD","IE0008369823.USD","LU1328277881.USD","IE0008368742.USD","BK1521","IE00B031HY20.USD","IE00B543WZ88.USD","LU0072913022.USD","LU0067412154.USD","LU1152091754.HKD","LU1813983027.USD","01093","LU1993786604.SGD","LU0880133367.SGD","LU2039709279.SGD","SG9999004220.SGD","LU0315179316.USD","LU1807302812.USD","LU1226288253.USD","LU1226288170.HKD","LU1960683339.HKD","HK0000165453.HKD","LU0140636845.USD","LU1152091168.USD","LU1226287875.USD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1191","BK1515","LU1951186391.HKD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU0326950275.SGD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662068944","title":"石药集团(01093.HK)：SYH2069注射液用于超重或肥胖成人患者体重管理的II期临床试验在中国首个研究中心正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2662068944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662068944?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:46","pubTimestamp":1787906788,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","BK1521","LU0326950275.SGD","LU0315179316.USD","IE00B5MMRT66.SGD","LU1226287875.USD","KURE","IE0008368742.USD","LU2039709279.SGD","LU1226288170.HKD","SG9999004220.SGD","LU0140636845.USD","LU0072913022.USD","LU1807302812.USD","LU1226288253.USD","LU1152091754.HKD","LU0067412154.USD","LU0314109678.HKD","HK0000165453.HKD","LU1226287529.USD","LU1226287792.SGD","IE00BZ08YT58.USD","BK1191","LU0880133367.SGD","BK1515","IE00B543WZ88.USD","LU1008478684.HKD","LU1328277881.USD","LU1993786604.SGD","IE0008369823.USD","LU1951186391.HKD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU1960683339.HKD","LU0501845795.SGD","01093","LU1813983027.USD","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111479853","title":"石药集团（01093.HK）在华启动SYH2069注射液II期肥胖管理临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1111479853","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111479853?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:37","pubTimestamp":1787906277,"startTime":"0","endTime":"0","summary":"2026年8月28日，石药集团有限公司公告称，其自主研发的SYH2069注射液用于超重或肥胖成人体重管理的II期临床试验已在中国首个研究中心正式启动。此次试验为多中心、随机、双盲、安慰剂对照、平行设计，旨在评估SYH2069在非糖尿病肥胖参与者中的有效性与安全性，当前受试者招募与筛选工作正在推进。在临床前研究中，SYH2069已展现良好的靶点活性及可控的安全性。石药集团表示，将严格按照试验方案推进II期临床研究，进一步验证SYH2069的疗效与安全性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165082962","title":"石药集团SYH2092注射液获准在华开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1165082962","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165082962?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:23","pubTimestamp":1787826196,"startTime":"0","endTime":"0","summary":"2026年8月27日，石药集团有限公司发布自愿公告称，其自主研发的高活性胰澱素受体激动剂SYH2092注射液已获国家药品监督管理局批准，可在中国开展临床试验。公告显示，SYH2092通过优化激动活性和脂肪酸修饰，旨在在保持可控耐受性的同时提升疗效，并延长体内半衰期。公司表示，该产品有望为肥胖患者体重管理及2型糖尿病成人患者血糖控制带来新的临床获益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188360112","title":"石药集团强效胰淀素受体激动剂（SYH2092注射液）获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1188360112","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188360112?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:20","pubTimestamp":1787826014,"startTime":"0","endTime":"0","summary":"石药集团宣布，其自主研发的强效胰淀素受体激动剂——SYH2092注射液，已正式获得中国国家药品监督管理局的临床试验批准。据悉，SYH2092注射液作为一种高活性的胰淀素受体激动剂，其作用机制独特，旨在通过精准靶向相关受体，为特定疾病领域提供新的治疗选择。石药集团表示，将严格遵循相关法规和科学准则，高效、严谨地推进该产品的临床试验进程，并期待其未来能够顺利上市，造福患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288253.USD","KURE","IE00BZ08YR35.GBP","LU1813983027.USD","01093","LU0314109678.HKD","SG9999004220.SGD","LU1807302812.USD","LU0880133367.SGD","LU1226287875.USD","LU1226288170.HKD","LU1152091168.USD","LU1226287529.USD","LU2039709279.SGD","IE00B031HY20.USD","IE00B5MMRT66.SGD","LU0067412154.USD","IE00B543WZ88.USD","LU1008478684.HKD","LU1993786604.SGD","HK0000165453.HKD","LU0072913022.USD","IE0008369823.USD","LU1960683339.HKD","IE0008368742.USD","LU1328277881.USD","BK1191","LU1951186391.HKD","LU0140636845.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","BK1521","LU1152091754.HKD","BK1515","LU0315179316.USD","IE00BZ08YT58.USD","LU0501845795.SGD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662772216","title":"【特约大V】邓声兴：PCE超预期加息升温，恒指或承压考验两万六","url":"https://stock-news.laohu8.com/highlight/detail?id=2662772216","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662772216?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:28","pubTimestamp":1787801339,"startTime":"0","endTime":"0","summary":"国指升88点或1.05%，报8533点。标指微挫0.02%，报7675点；纳指跌0.08%，报26130点；重磅股中，辉达周三收市后公布业绩，股价收市下滑1.6%。PCE超预期加息升温，恒指或承压考验两万六。小核酸平台方面，8月12日收到阿斯利康就siRNA药物开发合作的3,000万美元首付款。石药集团正处于业绩爆发、BD持续兑现及创新管线密集收获的三重利好交汇点，中线估值重构空间值得跟进。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/MTBhNmJhMjNhYmJjNDg2MTczNjQ3NDEwNzUzMg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MTBhNmJhMjNhYmJjNDg2MTczNjQ3NDEwNzUzMg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989691","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HBBD.SI","LU0543330483.HKD","BK1618","LU0029874905.USD","LU0251144936.SGD","LU0029875118.USD","LU0516422440.USD","LU0823426308.USD","LU1868838027.USD","LU0320764243.SGD","LU1303224171.USD","HSI","SG9999006514.SGD","LU0048388663.USD","LU1720051017.SGD","LU0828237940.HKD","LU0320764599.SGD","LU0314109678.HKD","LU2097828631.EUR","HSTECH","LU1868837565.USD","LU2097828805.USD","LU0048580855.USD","LU0819121731.USD","BK1591","LU2293587155.HKD","LU1008478684.HKD","LU0540923850.HKD","LU0784639295.USD","LU1366334578.USD","LU2242644610.SGD","LU1813983027.USD","LU2152927971.USD","LU0293314216.USD","IE00B031HY20.USD","IE00B0JY6N72.USD","LU0608807946.USD","LU0572944931.SGD","LU0345776255.USD","LU0370786039.SGD","LU0819123356.HKD","LU1282648689.USD","LU1051768304.USD","BK1588","LU0865486749.SGD","SG9999014674.SGD","LU0868486357.SGD","LU0880133367.SGD","LU0164872284.USD","SG9999001093.SGD","LU0072913022.USD","LU0572940350.SGD","LU0127658192.USD","LU0164865239.USD","89988","LU0455707207.USD","BK1584","LU0449509016.USD","LU0672654166.SGD","LU1323998911.USD","LU1242518931.SGD","LU1688375341.USD","LU0149534421.HKD","LU0541501648.USD","BK1142","LU0577902611.USD","LU0261947096.USD","LU0047713382.USD","IE00BPRC5H50.USD","513600","LU0543330566.HKD","SG9999001689.USD","LU1242518857.USD","LU0348788117.USD","LU0197773673.USD","LU0130103400.USD","LU0261950983.USD","LU0315178854.USD","LU1282649810.SGD","LU0348735423.USD","LU0823038988.USD","LU0054450605.USD","LU0307460666.USD","LU0315179316.USD","SG9999006597.SGD","KWEB","LU0117841782.USD","BABA","LU1880398471.USD","BK1575","LU1282651048.USD","LU1831875114.USD","LU0608807433.USD","LU0593848301.USD","LU1956131251.USD","LU0648000940.SGD","LU2294711473.HKD","SG9999001051.SGD","LU0499858438.USD","LU0607220059.USD","SGXZ86797644.SGD","LU0051755006.USD","LU0675040207.SGD","LU1226288253.USD","LU1044876610.USD","IE00BMPRXN33.USD","LU1481107354.HKD","LU0650527681.SGD","LU2125910849.SGD","LU0823413660.USD","LU1770034418.SGD","BK1501","LU0708995153.HKD","IE00BZ08YT58.USD","LU0516422366.SGD","LU0396098781.USD","SG9999001903.USD","LU0630378429.USD","BK1586","LU0791590937.USD","LU0128522744.USD","LU2097828474.EUR","FDNI","LU0043850808.USD","LU0886674414.USD","LU1152091754.HKD","LU1720051108.HKD","LU0828237510.HKD","03115","LU0823426480.USD","LU1226287875.USD","LU0011963245.USD","LU0130518102.USD","LU0831103253.SGD","LU0823397103.USD","SG9999001226.SGD","LU0214875030.USD","BK1608","LU0561508036.HKD","LU0594300179.USD","LU2257852520.SGD","LU0132412106.USD","LU1282649067.USD","LU0516423091.SGD","LU0320764755.SGD","LU1023057109.AUD","LU1960683339.HKD","LU1188198961.HKD","IE00B543WZ88.USD","LU0898667661.SGD","LU2449936058.SGD","HK0000286598.CNH","LU0588546209.SGD","HK0000306685.HKD","LU2476274720.SGD","LU1226287529.USD","LU0329678170.USD","LU1048596156.SGD","LU0873338254.USD","LU0287142896.SGD","HK0000320264.USD","LU0821914370.USD","LU1224444064.USD","LU2357305700.SGD","LU0823039010.USD","LU0979878070.USD","LU0762541174.USD","SG9999000459.SGD","LU1981816686.USD","LU1951186391.HKD","LU2045819591.USD","BK1615","LU0384037296.USD","SG9999002463.SGD","LU2125910500.SGD","LU0588545904.SGD","HK0000320223.HKD","LU0140636845.USD","LU0254981946.USD","LU0605514214.HKD","LU0762542818.HKD","LU0449515922.USD","LU0259732245.USD","LU1504937902.USD","LU0348816934.USD","MCHmain","LU0181495838.USD","SG9999002562.SGD","LU0106252389.USD","LU1548497426.USD","LU0228367735.SGD","LU0488056044.USD","LU1794554557.SGD","BK1191","LU0345775950.USD","LU0541502299.USD","LU0359201885.HKD","09115","LU0163747925.USD","LU0918141705.HKD","IE00BZ08YR35.GBP","BK1515","LU0264606111.USD","HK0000165453.HKD","LU0594300419.USD","IE0008368742.USD","LU1328615791.USD","LU0572939691.SGD","LU1769817179.HKD","IE0032431581.USD","LU0871576103.HKD","LU0210526637.USD","LU1282651121.HKD","LU0096374516.USD","LU2097828557.USD","BKF","LU0502904849.HKD","LU0651947912.USD","LU1115378108.SGD","IE00B3M56506.USD","LU0348814723.USD","LU0501845795.SGD","LU0117844026.USD","LU0588545730.USD","HK0000306701.USD","LU0359202008.SGD","LU2778985437.USD","LU0417516738.SGD","83115","LU0106959298.USD","LU1196710864.SGD","LU0084288322.USD","LU0326950275.SGD","LU0862451837.USD","LU0577902298.EUR","IE00B0169N27.USD","LU0128522157.USD","LU0431992006.USD","HHImain","LU0737861699.HKD","LU0235996351.USD","LU1366334651.USD","LDEM","LU0348827113.USD","01093","LU1642822792.SGD","LU0348805143.USD","LU0634319403.HKD","07300","LU0054237671.USD","LU0642271901.SGD","LU0052750758.USD","LU2476274308.USD","SGXZ62798434.SGD","LU0417516571.SGD","LU1515016050.SGD","LU1880383440.USD","LU0823397285.USD","LU1808992512.USD","LU0856984785.SGD","LU0577902538.SGD","SG9999004220.SGD","IE0003895053.USD","LU0577902371.SGD","LU0708995583.HKD","LU0210527791.USD","82800","LU0531970944.HKD","09988","LU1720050803.USD","LU0196878994.USD","LU2097829019.USD","LU0244354667.USD","LU0651946864.USD","LU1328277881.USD","LU1226288170.HKD","LU0469268626.HKD","LU2039709279.SGD","LU0823041008.USD","LU1655091459.SGD","LU1211504680.USD","LU1770036033.HKD","LU1044874839.SGD","LU0499858602.USD","LU1152091168.USD","03037","LU0106259558.USD","07500","IE0008369823.USD","LU1282649141.HKD","LU1993786604.SGD","LU0823040885.USD","ALBmain","LU0456846285.SGD","KURE","CXSE","LU0588545490.SGD","02800","LU0862451753.SGD","LU0049853897.USD","BK1610","LU1769817096.USD","LU0630378692.HKD","LU0348825331.USD","LU0061477393.USD","LU0791591158.USD","LU0477156797.USD","03419","LU0700851271.USD","BK1249","LU0831093199.SGD","LU1880398554.USD","LU1961090484.USD","LU0918141887.USD","LU1048588211.SGD","LU0640798160.USD","LU0067412154.USD","LU0328353924.USD","LU2087589342.USD","LU0737861772.HKD","LU0531971595.HKD","LU0348783233.USD","LU1226287792.SGD","LU0149721374.USD","LU1044875133.USD","LU0228659784.USD","LU0648948544.HKD","LU2399975544.HKD","LU1251922891.USD","LU0797268264.HKD","LU0197773160.USD","LU0823413587.USD","02833","LU0164880469.USD","BK1502","LU0348783662.USD","LU0143863784.USD","LU1316542783.SGD","LU0456827905.SGD","HK0000107257.USD","LU0329678337.USD","LU0417516902.SGD","BK1521","LU0611395673.USD","SGXZ90724238.SGD","LU2226246903.HKD","LU0441854154.USD","LU0516423174.USD","LU1105468828.SGD","LU1224709979.USD","LU0165289439.USD","LU1568876251.USD","IE00BZ08YS42.EUR","LU0327786744.USD","LU1568876335.HKD","SG9999000327.SGD","LU0762540952.USD","LU0211977185.USD","LU1810669033.SGD","IE0008368304.USD","LU1719994722.HKD","LU0359201612.USD","IE00BMPRXR70.SGD","LU0229945570.USD","LU3063872942.SGD","LU0348784397.USD","IE0034224299.USD","LU2097828714.EUR","LU0173614495.USD","LU1051769294.HKD","LU0169518387.USD","HK0000151867.HKD","LU0143863198.USD","LU0048597586.USD","BK1517","IE00B5MMRT66.SGD","LU0039217434.USD","LU0577902454.USD","SG9999002828.SGD","LU0890818403.SGD","LU1201861165.SGD","LU1880383366.USD","LU2488822045.USD","LU0516422952.EUR","LU0231483743.USD","07200","LU1807302812.USD","LU0072462343.USD","LU0589944569.HKD","LU1048484197.HKD","LU1439103000.SGD","LU0463099449.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729977","title":"【券商聚焦】国投证券：创新药有望开启新一轮高景气周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729977","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662729977?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:29","pubTimestamp":1787794154,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券研究指，医药景气新周期背景下，国内创新药产业链加速崛起。近年国家多举措全链条支持创新药发展，叠加国内得天独厚的人才储备和研发效率等多维优势，国内创新药持续加速崛起且逐步具备全球竞争力。与此同时，海外MNC陆续面临专利悬崖困境，对外采购和扩充创新管线需求与日俱增，国内创新药企顺势而为，以海外授权BD等形式实现创新出海，创新药有望开启新一轮高景气周期。风险提示：产品研发及审批速度低于预期；产品降价超预期风险；海外BD授权不及预期风险；计算及假设不及预期风险。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989630","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","159992","01177","LU1807302812.USD","LU0463099449.HKD","IE0008369823.USD","LU0417516738.SGD","IBBQ","LU0307460666.USD","02142","LU1969619763.USD","LU2242644610.SGD","LU0348825331.USD","IE00BPRC5H50.USD","02269","161027","LU1226287875.USD","LU0455707207.USD","01801","MEDX","06160","SG9999002562.SGD","09688","LU0039217434.USD","LU1770034418.SGD","LNGR","KURE","SG9999004220.SGD","KCE","01093","LU0314109678.HKD","LU0634319403.HKD","LU0140636845.USD","LU0348783233.USD","BK1589","02616","LU0516423091.SGD","LU0880133367.SGD","09926","LU0359201612.USD","06978","LU0051755006.USD","06185","LU0348767384.USD","LU1813983027.USD","LU1794554557.SGD","09995","01877","LU0516422952.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101550487","title":"石药集团（01093）创新抗肿瘤药SYS 6090获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1101550487","media":"公告速递","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101550487?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:16","pubTimestamp":1787739373,"startTime":"0","endTime":"0","summary":"2026年8月26日，石药集团有限公司发布自愿公告称，其自主研发的首创PD-1/IL-15双特异性融合蛋白SYS 6090已获美国食品药品监督管理局授予快速通道资格，用于治疗在标准系统性治疗后出现疾病进展的微卫星稳定或错配修复功能完整型转移性结直肠癌患者。SYS 6090通过同时阻断PD-1并激活IL-15信号通路，旨在重塑免疫“冷”肿瘤微环境并激活耗竭效应细胞。石药集团表示，FDA的快速通道资格将有助于加快SYS 6090在美国及全球范围内的开发与审评进程。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797913","title":"石药集团(01093)：SYS6090 (JMT108)获美国FDA授予快速通道资格用于治疗MSS/pMMR型mCRC患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797913","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662797913?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:13","pubTimestamp":1787739180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的一款首创PD-1/IL-15双特异性融合蛋白SYS6090 (该产品)已获美国食品药品监督管理局授予快速通道资格，用于治疗既往经标准系统性治疗后出现疾病进展的微卫星稳定或错配修复功能完整型转移性结直肠癌患者。MSS/pMMR型mCRC被认为是典型的冷肿瘤，对标准免疫疗法应答有限。FDA授予快速通道资格，是对该产品用于治疗严重或危及生命疾病潜力的认可，将有助于加快其在美国乃至全球范围内的开发与审批进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288253.USD","LU2039709279.SGD","01093","LU1152091754.HKD","IE00B543WZ88.USD","LU1993786604.SGD","LU0314109678.HKD","LU1226287875.USD","LU1807302812.USD","LU0501845795.SGD","KURE","BK1191","BK1515","BK4585","LABU","LU0326950275.SGD","LU1226287529.USD","SG9999004220.SGD","IE00BZ08YT58.USD","HK0000165453.HKD","LU0140636845.USD","IE00BZ08YR35.GBP","LU1960683339.HKD","LU1951186391.HKD","BK4588","LU0067412154.USD","LU1813983027.USD","IE0008368742.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","LU1008478684.HKD","IE00B031HY20.USD","BK4113","MSS","LU1226287792.SGD","BK1521","LU1152091168.USD","LU0072913022.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","IE0008369823.USD","LU1328277881.USD","LU0315179316.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797313","title":"石药集团(01093)：SYS6010用于EGFR TKI治疗失败的EGFR突变型局部晚期或转移性NSCLC III期临床研究达到预设的主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797313","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662797313?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:06","pubTimestamp":1787738801,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的SYS6010(该产品)于近日在评估该产品单药对比含铂化疗用于表皮生长因子受体酪氨酸激酶抑制剂治疗失败的EGFR突变型局部晚期或转移性非小细胞肺癌的III期临床研究中，经独立数据监察委员会审核评估，已成功达到无进展生存期这一预设的主要研究终点。目前，EGFRTKI是EGFR突变晚期NSCLC患者的一线标占治疗方案。然而，患者在接受EGFRTKI治疗后将不可避免地产生耐药，而耐药后的治疗方案疗效有限。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288253.USD","LU2039709279.SGD","01093","LU1152091754.HKD","IE00B543WZ88.USD","LU1993786604.SGD","LU0314109678.HKD","LU1226287875.USD","LU1807302812.USD","LU0501845795.SGD","KURE","BK1191","BK4134","BK1515","LU1226287529.USD","LU0326950275.SGD","III","SG9999004220.SGD","IE00BZ08YT58.USD","HK0000165453.HKD","LU0140636845.USD","IE00BZ08YR35.GBP","LU1960683339.HKD","LU1951186391.HKD","LU0067412154.USD","LU1813983027.USD","IE0008368742.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","LU1008478684.HKD","IE00B031HY20.USD","LU1226287792.SGD","BK1521","LU1152091168.USD","LU0072913022.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","IE0008369823.USD","LU1328277881.USD","LU0315179316.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121115717","title":"石药集团SYSA-6010在III期SYNSTAR-01研究中达到无进展生存期主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1121115717","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121115717?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:03","pubTimestamp":1787738592,"startTime":"0","endTime":"0","summary":"石药集团宣布，其自主研发的SYSA-6010药物在III期SYNSTAR-01临床试验中成功达到了无进展生存期的主要终点。据悉，SYNSTAR-01研究是一项多中心、随机、双盲、对照设计的III期临床试验，旨在评估SYSA-6010在特定适应症中的疗效与安全性。试验结果显示，与对照组相比，SYSA-6010显著延长了患者的中位无进展生存期，且差异具有统计学意义。业界分析人士指出，SYSA-6010若最终获批，有望为相关患者提供新的治疗选择，并进一步巩固石药集团在创新药领域的市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","IE00BZ08YS42.EUR","IE0008369823.USD","IE00BZ08YR35.GBP","IE00B031HY20.USD","IE00B543WZ88.USD","LU1807302812.USD","LU1813983027.USD","LU1960683339.HKD","KURE","LU0140636845.USD","LU1226288170.HKD","BK1515","01093","BK1191","LU1328277881.USD","LU2039709279.SGD","LU1226287529.USD","LU1152091754.HKD","LU1226287875.USD","LU0067412154.USD","LU0314109678.HKD","LU0501845795.SGD","HK0000165453.HKD","LU0315179316.USD","LU0326950275.SGD","LU0072913022.USD","LU1008478684.HKD","IE0008368742.USD","LU0880133367.SGD","LU1152091168.USD","LU1951186391.HKD","LU1226288253.USD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","LU1993786604.SGD","BK1521","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166882159","title":"异动解读｜石药集团盘中上涨3.13%，RSV疫苗获FDA临床试验批准叠加多家大行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1166882159","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166882159?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:43","pubTimestamp":1787708599,"startTime":"0","endTime":"0","summary":"8月26日，石药集团盘中上涨3.13%，报9.69港元，成交额2.26亿港元。消息面上，公司8月25日公告其自主研发的重组呼吸道合胞病毒疫苗SYS 6057已获美国FDA批准在美国开展临床试验，适应症为60岁及以上人群预防RSV引起的下呼吸道疾病，系公司第二款获批临床的重组蛋白疫苗。此外，公司中期业绩发布后，高盛、瑞银、大摩、花旗等多家国际大行密集上调目标价至11.2至14港元区间，普遍维持买入评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团异动拉升，RSV疫苗获批临床","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662758805","title":"石药集团(01093.HK)遭汇添富基金减持3912.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662758805","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662758805?lang=zh_cn&edition=full","pubTime":"2026-08-25 21:47","pubTimestamp":1787665623,"startTime":"0","endTime":"0","summary":"格隆汇8月25日丨根据联交所最新权益披露资料显示，2026年8月20日，石药集团(01093.HK)遭汇添富基金管理股份有限公司在场内以每股均价9.7533港元减持3912.4万股，涉资约3.82亿港元。\r\n\r\n　　减持后，汇添富基金管理股份有限公司最新持股数目为568,576,800股，持股比例由5.27%下降至4.93%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/25/20260825888505.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/25/20260825888505.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260825/32347058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1813983027.USD","BK1521","BK1515","LU1152091754.HKD","IE0008369823.USD","SG9999004220.SGD","IE00BZ08YT58.USD","IE0008368742.USD","LU1226288253.USD","KURE","LU0880133367.SGD","LU0072913022.USD","LU1226287529.USD","LU1960683339.HKD","LU0501845795.SGD","HK0000165453.HKD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","01093","LU0140636845.USD","LU1951186391.HKD","IE00BZ08YS42.EUR","LU1807302812.USD","LU2039709279.SGD","LU0067412154.USD","LU0315179316.USD","LU1226287792.SGD","LU1328277881.USD","LU0326950275.SGD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU1226288170.HKD","BK1191","LU1993786604.SGD","LU0314109678.HKD","LU1008478684.HKD","LU1152091168.USD","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":0.0758},{"period":"3month","weight":0.3016},{"period":"6month","weight":0.0371},{"period":"1year","weight":-0.1282},{"period":"ytd","weight":0.1195}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0214},{"period":"3month","weight":-0.0118},{"period":"6month","weight":0.0003},{"period":"1year","weight":-0.0112},{"period":"ytd","weight":-0.0117}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门：成药部门、抗生素（中间体及原料药）部门、维生素C（原料药）部门及咖啡因及其他（原料药）部门，分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094313},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017543},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057684},{"month":5,"riseRate":0.59375,"avgChangeRate":0.042479},{"month":6,"riseRate":0.3125,"avgChangeRate":0.001853},{"month":7,"riseRate":0.393939,"avgChangeRate":0.015989},{"month":8,"riseRate":0.454545,"avgChangeRate":0.011919},{"month":9,"riseRate":0.484848,"avgChangeRate":0.000291},{"month":10,"riseRate":0.5625,"avgChangeRate":0.01001},{"month":11,"riseRate":0.46875,"avgChangeRate":0.006831},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013329}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}